Biologic agents, including omalizumab (anti-IgE), mepolizumab (anti-IL-5), and dupilumab (anti-IL4/13), have been approved for CRSwNP treatment, confirming the pathogenetic role of the targeted immunoglobulin/cytokines. The gene discussed is IGHE; the disease is chronic rhinosinusitis with nasal polyps.